Study of Pembrolizumab (MK-3475) and Pembrolizumab with Other Investigational Agents in Participants with High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Trial Identifier:	3475-057
Sponsor:	MSD
Start Date:	February 2016
Primary Completion Date:	August 2026
Study Completion Date:	August 2030
Condition:	Bladder Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary
	Protocol Plain Language Summary

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.